UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2014
Durata Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35599 | 27-1247903 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
200 South Wacker Drive, Suite 2550
Chicago, Illinois 60606
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (312) 219-7000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders.
Durata Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on May 21, 2014. The following is a summary of the matters voted on at that meeting.
| (a) | The stockholders of the Company elected Brenton K. Ahrens and Nicole Vitullo as Class II directors to hold office until the 2017 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The results of the stockholders’ votes with respect to the election of such Class II directors were as follows: |
| Name |
Votes For | Votes Withheld | Broker Non-Votes | |||||||||
| Brenton K. Ahrens |
20,921,369 | 30,355 | 4,488,422 | |||||||||
| Nicole Vitullo |
20,892,667 | 59,057 | 4,488,422 | |||||||||
| (b) | The stockholders of the Company approved an amendment and restatement of the Company’s 2012 Stock Incentive Plan. The results of the stockholders’ vote with respect to such approval were as follows: |
| For |
Against |
Abstain |
Broker Non-Votes | |||||
| 20,559,753 |
379,297 | 12,674 | 4,488,422 | |||||
| (c) | The stockholders of the Company ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm. The results of the stockholders’ vote with respect to such ratification were as follows: |
| For |
Against |
Abstain |
Broker Non-Votes | |||||
| 25,376,008 |
55,251 | 8,887 | 0 | |||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DURATA THERAPEUTICS, INC. | ||||||
| Date: May 21, 2014 | By: | /s/ Corey N. Fishman | ||||
| Corey N. Fishman | ||||||
| Chief Financial Officer and Chief Operating Officer | ||||||
| (Principal Financial and Accounting Officer) | ||||||
3